Is Sat Kartar overvalued or undervalued?

As of 22 September 2025, the valuation grade for Sat Kartar has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 25.33, an EV to EBITDA ratio of 15.74, and a ROCE of 48.39%.
In comparison to its peers, Sat Kartar's valuation stands out, particularly against Sun Pharma, which has a PE ratio of 34.24 and is categorized as expensive, and Cipla, which is attractive with a PE ratio of 23.1. The PEG ratio for Sat Kartar is notably low at 0.00, further supporting the undervaluation thesis. Despite recent stock performance lagging behind the Sensex, particularly over the past month, the strong financial metrics suggest that Sat Kartar presents a compelling investment opportunity.